{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:13:42Z","timestamp":1789496022478,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of insulin degludec\/liraglutide (IDegLira) compared with its individual components in Japanese people with type 2 diabetes (T2D) uncontrolled on an oral antidiabetic drug (OAD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This 52\u2010week, open\u2010label, multicentre, treat\u2010to\u2010target trial randomized participants (n = 819) 1:1:1 to IDegLira, liraglutide 1.8 mg or degludec, as add\u2010on to their pre\u2010trial OAD. The maximum IDegLira dose was 50 dose steps (50\u2009U degludec\/1.8 mg liraglutide), there was no maximum dose for degludec, and both were titrated based on individual blood glucose measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 52\u2009weeks, glycated haemoglobin (HbA1c) decreased by 26\u2009mmol\/mol with IDegLira vs 20\u2009mmol\/mol with degludec and liraglutide: estimated treatment differences were \u22126.91\u2009mmol\/mol (95% confidence interval [CI] \u20138.18; \u22125.64) and \u22125.30\u2009mmol\/mol (95% CI \u22126.58; \u22124.03), confirming non\u2010inferiority of IDegLira to degludec and superiority of IDegLira to liraglutide (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.0001 for both [primary endpoint]). Mean body weight changes were 2.9 kg, 4.1 kg and \u22121.0 kg with IDegLira, degludec and liraglutide, respectively, showing superiority of IDegLira versus degludec (\n                      <jats:italic>P<\/jats:italic>\n                      = .0001), but a significant difference in favour of liraglutide (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.0001). Rates of severe or blood glucose\u2010confirmed hypoglycaemia for IDegLira were lower versus degludec (rate ratio 0.48 [95% CI 0.35; 0.68];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.0001), but higher versus liraglutide (rate ratio 37.58 [95% CI 19.80; 71.31];\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.0001). Mean daily total insulin dose was lower with IDegLira (27.7 U) versus degludec (34.8 U;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.0001). Overall adverse event (AE) rates were similar. In total, 34.9%, 22.9% and 41.8% of IDegLira\u2010, degludec\u2010 and liraglutide\u2010treated participants experienced gastrointestinal AEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IDegLira was superior to degludec and liraglutide in terms of HbA1c reduction and superior to degludec in terms of body weight change and rates of hypoglycaemia in Japanese people with T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13856","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T06:01:39Z","timestamp":1565676099000},"page":"2674-2683","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Superior efficacy with a fixed\u2010ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin\u2010na\u00efve Japanese patients with type 2 diabetes in a phase 3, open\u2010label, randomized trial"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-0565","authenticated-orcid":false,"given":"Kohei","family":"Kaku","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Kawasaki Medical School  Kurashiki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine Kumamoto University  Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Tanizawa","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine Yamaguchi University  Ube Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bue","family":"Ross Agner","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Nishida","sequence":"additional","affiliation":[{"name":"Novo Nordisk Pharma Ltd  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattis","family":"Ranthe","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuya","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Nutrition Kyoto University Graduate School of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Federation ID. IDF Atlas 8th Edition: Japan country report.http:\/\/reports.instantatlas.com\/report\/view\/846e76122b5f476fa6ef09471965aedd\/JPN. Accessed October 2018."},{"key":"e_1_2_9_3_1","first-page":"36","article-title":"Trends in the epidemiology of patients with diabetes in Japan","volume":"53","author":"Morimoto A","year":"2010","journal-title":"Japan Med Assoc J"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0213-8"},{"key":"e_1_2_9_5_1","first-page":"698","article-title":"Epidemiology of diabetes","volume":"42","author":"Forouhi NG","year":"2014","journal-title":"Medicine (Abingdon)"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.726"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12333"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0598"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(02)00177-8"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12810"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2011"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S009"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.03.012"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-2-201101180-00300"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2462"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12539"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13132"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm031"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12498"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70174-3"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1114"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13043"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12892"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0218-3"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0785"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13256"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13666"},{"key":"e_1_2_9_30_1","unstructured":"Novo Nordisk. Xultophy\u00ae Summary of Product Characteristics.2018.https:\/\/www.medicines.org.uk\/emc\/product\/3469. Accessed July 2018."},{"key":"e_1_2_9_31_1","unstructured":"Novo Nordisk. Xultophy\u00ae 100\/3.6 Prescribing Information (PI).2016.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208583s000lbl.pdf. Accessed November 2018."},{"key":"e_1_2_9_32_1","unstructured":"Novo Nordisk. Victoza\u00ae Summary of Product Characteristics.2017.https:\/\/www.medicines.org.uk\/emc\/product\/6585\/smpc. Accessed July 2018."},{"key":"e_1_2_9_33_1","volume-title":"Guidance for Industry: Diabetes Mellitus \u2010 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes","author":"US Department of Health and Human Services, Food and Drug Administration","year":"2008"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12972"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12731"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2237w"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.03.018"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0051-1"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.12.015"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13856","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13856","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13856","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:39:19Z","timestamp":1761863959000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1111\/dom.13856"],"URL":"https:\/\/doi.org\/10.1111\/dom.13856","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.13856\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v1\/review5","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v2\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.13856\/v2\/response1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"2019-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}